Biopharmaceutical CMO Market Analysis and Forecast to 2032: By Product (Biologics, Biosimilars), Source (Mammalian, Non-mammalian), Service (Contract Manufacturing, Process Development, Packaging, Others), and Region

A Contract Manufacturing Organization (CMO), also known as a Biopharmaceutical CMO, is a company that provides manufacturing and other services to the pharmaceutical and biotechnology industries. CMOs are an important part of the pharmaceutical supply chain, and they play a vital role in bringing new drugs and therapies to market.

CMOs specialize in the manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). They also provide a range of other services, such as analytical testing, formulation development, and packaging. CMOs are typically large, multinational companies with extensive experience in drug manufacturing.

The global CMO market is growing rapidly, driven by the increasing outsourcing of drug manufacturing by pharmaceutical and biotechnology companies. The market is also being driven by the need for increased capacity and flexibility, as well as the desire to reduce costs.

Key Trends

The key trends in Biopharmaceutical CMO technology are:

1. The use of biotechnology to develop new drugs and therapies.

2. The use of cell culture and fermentation technologies to produce biopharmaceuticals.

3. The use of monoclonal antibodies and other protein-based drugs.

4. The use of nucleic acid-based drugs and gene therapy.

Key Drivers

The biopharmaceutical CMO market is driven by the increasing demand for biopharmaceuticals, the need for specialized manufacturing facilities, and the increasing number of biopharmaceutical companies. The biopharmaceutical industry is growing at a rapid pace, and the number of biopharmaceutical companies is increasing. This is resulting in an increased demand for CMOs. CMOs are specialized manufacturing facilities that are required for the production of biopharmaceuticals. They are required to meet the stringent quality standards set by the FDA. The increasing number of biopharmaceutical companies is resulting in an increased demand for CMOs.

Restraints & Challenges

The biopharmaceutical CMO market is facing a number of key restraints and challenges. Firstly, the market is highly competitive and there are a large number of players operating in the space. This makes it difficult for new entrants to gain a foothold in the market. Secondly, the market is capital intensive and requires significant investment in research and development. This is a major barrier for small and medium sized companies. Thirdly, the regulatory environment is constantly changing and this makes it difficult for companies to keep up with the latest regulations. Finally, the market is reliant on a small number of key customers and this makes it difficult to diversify revenue streams.

Market Segments

The biopharmaceutical CMO market report is bifurcated on the basis of product, source, service, and region. On the basis of product, it is segmented into biologics and biosimilars. Based on source, it is analyzed across mammalian and non-mammalian. By service, it is categorized into contract manufacturing, process development, packaging, and others. Region-wise, it is studied across North America, Europe, Asia-Pacific, and rest of the World.

Key Player

The biopharmaceutical CMO market report includes players such as Toyobo Co., Ltd., Samsung Biologics, Patheon, Lonza AG, WuXi Biologics, AbbVie Inc., Binex Co., Ltd., JRS Pharma, Biomeva GmbH, and ProBioGen AG.

Why GIS?

Table of Contents

Chapter 1. Market Introduction
1.1. Objectives of the Study
1.2. Market Definition and Research & Scope
1.3. Research Methodologies
1.4. Market Estimation Techniques

Chapter 2. Executive Summary
2.1. Summary
2.2. Key Highlights of the Market

Chapter 3. Biopharmaceutical CMO Market Outlook
3.1. Biopharmaceutical CMO Market Segmentation
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.1.1. Driver 1
3.2.1.2. Driver 2
3.2.1.3. Driver 3
3.2.2. Market Restraints
3.2.2.1. Restraint 1
3.2.2.2. Restraint 2
3.2.3. Market Opportunities
3.2.3.1. Opportunity 1
3.2.3.2. Opportunity 2
3.3. Porter’s Five Forces Analysis
3.3.1. Threat of New Entrants
3.3.2. Threat of Substitutes
3.3.3. Bargaining Power of Buyers
3.3.4. Bargaining Power of Supplier
3.3.5. Competitive Rivalry
3.4. PESTLE Analysis
3.5. Value Chain Analysis
3.5.1. Raw Material Suppliers
3.5.2. Manufacturers
3.5.3. Wholesalers and/or Retailers
3.6. Impact of the Russia and Ukraine War on the Global Biopharmaceutical CMO Market

Chapter 4. Economic Impact of COVID-19
4.1. Overall Impact of COVID-19
4.2. Impact of COVID On the Global Biopharmaceutical CMO Market
4.3. Economic Impact Analysis

Chapter 5. Biopharmaceutical CMO Market by Product
5.1. Market Overview
5.2. Biologics
5.2.1. Market Size and Forecast, 2021-2031 ($Million)
5.2.2. Market Size and Forecast, by Region, 2021-2031 ($Million)
5.3. Biosimilars
5.3.1. Market Size and Forecast, 2021-2031 ($Million)
5.3.2. Market Size and Forecast, by Region, 2021-2031 ($Million)

Chapter 6. Biopharmaceutical CMO Market by Source
6.1. Market Overview
6.2. Mammalian
6.2.1. Market Size and Forecast, 2021-2031 ($Million)
6.2.2. Market Size and Forecast, by Region, 2021-2031 ($Million)
6.3. Non-mammalian
6.3.1. Market Size and Forecast, 2021-2031 ($Million)
6.3.2. Market Size and Forecast, by Region, 2021-2031 ($Million)

Chapter 7. Biopharmaceutical CMO Market by Service
7.1. Market Overview
7.2. Contract Manufacturing
7.2.1. Market Size and Forecast, 2021-2031 ($Million)
7.2.2. Market Size and Forecast, by Region, 2021-2031 ($Million)
7.3. Process Development
7.3.1. Market Size and Forecast, 2021-2031 ($Million)
7.3.2. Market Size and Forecast, by Region, 2021-2031 ($Million)
7.4. Packaging
7.4.1. Market Size and Forecast, 2021-2031 ($Million)
7.4.2. Market Size and Forecast, by Region, 2021-2031 ($Million)
7.5. Others
7.5.1. Market Size and Forecast, 2021-2031 ($Million)
7.5.2. Market Size and Forecast, by Region, 2021-2031 ($Million)

Chapter 8. Biopharmaceutical CMO Market, by Region
8.1. Overview
8.2. North America
8.2.1. Key Market Trends and Opportunities
8.2.2. North America Biopharmaceutical CMO Market Size and Forecast By Product, 2021-2031, ($Million)
8.2.3. North America Biopharmaceutical CMO Market Size and Forecast by Source, 2021-2031, ($Million)
8.2.4. North America Biopharmaceutical CMO Market Size and Forecast by Service, 2021-2031, ($Million)
8.2.5. North America Biopharmaceutical CMO Market Size and Forecast by Country, 2021-2031, ($Million)
8.2.6. The U.S.
8.2.6.1. The U.S. Biopharmaceutical CMO Market Size and Forecast By Product, 2021-2031, ($Million)
8.2.6.2. The U.S. Biopharmaceutical CMO Market Size and Forecast by Source, 2021-2031, ($Million)
8.2.6.3. The U.S. Biopharmaceutical CMO Market Size and Forecast by Service, 2021-2031, ($Million)
8.2.7. Canada
8.2.7.1. Canada Biopharmaceutical CMO Market Size and Forecast By Product, 2021-2031, ($Million)
8.2.7.2. Canada Biopharmaceutical CMO Market Size and Forecast by Source, 2021-2031, ($Million)
8.2.7.3. Canada Biopharmaceutical CMO Market Size and Forecast by Service, 2021-2031, ($Million)
8.2.8. Mexico
8.2.8.1. Mexico Biopharmaceutical CMO Market Size and Forecast By Product, 2021-2031, ($Million)
8.2.8.2. Mexico Biopharmaceutical CMO Market Size and Forecast by Source, 2021-2031, ($Million)
8.2.8.3. Mexico Biopharmaceutical CMO Market Size and Forecast by Service, 2021-2031, ($Million)
8.3. Europe
8.3.1. Key Market Trends and Opportunities
8.3.2. Europe Biopharmaceutical CMO Market Size and Forecast By Product, 2021-2031, ($Million)
8.3.3. Europe Biopharmaceutical CMO Market Size and Forecast by Source, 2021-2031, ($Million)
8.3.4. Europe Biopharmaceutical CMO Market Size and Forecast by Service, 2021-2031, ($Million)
8.3.5. Europe Biopharmaceutical CMO Market Size and Forecast by Country, 2021-2031, ($Million)
8.3.6. Germany
8.3.6.1. Germany Biopharmaceutical CMO Market Size and Forecast By Product, 2021-2031, ($Million)
8.3.6.2. Germany Biopharmaceutical CMO Market Size and Forecast by Source, 2021-2031, ($Million)
8.3.6.3. Germany Biopharmaceutical CMO Market Size and Forecast by Service, 2021-2031, ($Million)
8.3.7. France
8.3.7.1. France Biopharmaceutical CMO Market Size and Forecast By Product, 2021-2031, ($Million)
8.3.7.2. France Biopharmaceutical CMO Market Size and Forecast by Source, 2021-2031, ($Million)
8.3.7.3. France Biopharmaceutical CMO Market Size and Forecast by Service, 2021-2031, ($Million)
8.3.8. U.K.
8.3.8.1. U.K. Biopharmaceutical CMO Market Size and Forecast By Product, 2021-2031, ($Million)
8.3.8.2. U.K. Biopharmaceutical CMO Market Size and Forecast by Source, 2021-2031, ($Million)
8.3.8.3. U.K. Biopharmaceutical CMO Market Size and Forecast by Service, 2021-2031, ($Million)
8.3.9. Spain
8.3.9.1. Spain Biopharmaceutical CMO Market Size and Forecast By Product, 2021-2031, ($Million)
8.3.9.2. Spain Biopharmaceutical CMO Market Size and Forecast by Source, 2021-2031, ($Million)
8.3.9.3. Spain Biopharmaceutical CMO Market Size and Forecast by Service, 2021-2031, ($Million)
8.3.10. Italy
8.3.10.1. Italy Biopharmaceutical CMO Market Size and Forecast By Product, 2021-2031, ($Million)
8.3.10.2. Italy Biopharmaceutical CMO Market Size and Forecast by Source, 2021-2031, ($Million)
8.3.10.3. Italy Biopharmaceutical CMO Market Size and Forecast by Service, 2021-2031, ($Million)
8.3.11. Rest of Europe
8.3.11.1. Rest of Europe Biopharmaceutical CMO Market Size and Forecast By Product, 2021-2031, ($Million)
8.3.11.2. Rest of Europe Biopharmaceutical CMO Market Size and Forecast by Source, 2021-2031, ($Million)
8.3.11.3. Rest of Europe Biopharmaceutical CMO Market Size and Forecast by Service, 2021-2031, ($Million)
8.4. Asia-Pacific
8.4.1. Key Market Trends and Opportunities
8.4.2. Asia-Pacific Biopharmaceutical CMO Market Size and Forecast by Country, 2021-2031, ($Million)
8.4.3. Asia-Pacific Biopharmaceutical CMO Market Size and Forecast by Source, 2021-2031, ($Million)
8.4.4. Asia-Pacific Biopharmaceutical CMO Market Size and Forecast By Product, 2021-2031, ($Million)
8.4.5. Asia-Pacific Biopharmaceutical CMO Market Size and Forecast by Service, 2021-2031, ($Million)
8.4.6. China
8.4.6.1. China Biopharmaceutical CMO Market Size and Forecast By Product, 2021-2031, ($Million)
8.4.6.2. China Biopharmaceutical CMO Market Size and Forecast by Source, 2021-2031, ($Million)
8.4.6.3. China Biopharmaceutical CMO Market Size and Forecast By Service 2021-2031, ($Million)
8.4.7. India
8.4.7.1. India Biopharmaceutical CMO Market Size and Forecast By Product, 2021-2031, ($Million)
8.4.7.2. India Biopharmaceutical CMO Market Size and Forecast by Source, 2021-2031, ($Million)
8.4.7.3. India Biopharmaceutical CMO Market Size and Forecast by Service, 2021-2031, ($Million)
8.4.8. Japan
8.4.8.1. Japan Biopharmaceutical CMO Market Size and Forecast By Product, 2021-2031, ($Million)
8.4.8.2. Japan Biopharmaceutical CMO Market Size and Forecast by Source, 2021-2031, ($Million)
8.4.8.3. Japan Biopharmaceutical CMO Market Size and Forecast by Service, 2021-2031, ($Million)
8.4.9. South Korea
8.4.9.1. South Korea Biopharmaceutical CMO Market Size and Forecast By Product, 2021-2031, ($Million)
8.4.9.2. South Korea Biopharmaceutical CMO Market Size and Forecast by Source, 2021-2031, ($Million)
8.4.9.3. South Korea Biopharmaceutical CMO Market Size and Forecast by Service, 2021-2031, ($Million)
8.4.10. Rest of APAC
8.4.10.1. Rest of APAC Biopharmaceutical CMO Market Size and Forecast By Product, 2021-2031, ($Million)
8.4.10.2. Rest of APAC Biopharmaceutical CMO Market Size and Forecast by Source, 2021-2031, ($Million)
8.4.10.3. Rest of APAC Biopharmaceutical CMO Market Size and Forecast by Service, 2021-2031, ($Million)
8.5. Rest of the World
8.5.1. Key Market Trends and Opportunities
8.5.2. Rest of the World Biopharmaceutical CMO Market Size and Forecast By Product, 2021-2031, ($Million)
8.5.3. Rest of the World Biopharmaceutical CMO Market Size and Forecast by Source, 2021-2031, ($Million)
8.5.4. Rest of the World Biopharmaceutical CMO Market Size and Forecast by Service, 2021-2031, ($Million)
8.5.5. Rest of the World Biopharmaceutical CMO Market Size and Forecast by Country, 2021-2031, ($Million)
8.5.6. Latin America
8.5.6.1. Latin America Biopharmaceutical CMO Market Size and Forecast By Product, 2021-2031, ($Million)
8.5.6.2. Latin America Biopharmaceutical CMO Market Size and Forecast by Source, 2021-2031, ($Million)
8.5.6.3. Latin America Biopharmaceutical CMO Market Size and Forecast by Service, 2021-2031, ($Million)
8.5.7. Middle East
8.5.7.1. Middle East Biopharmaceutical CMO Market Size and Forecast By Product, 2021-2031, ($Million)
8.5.7.2. Middle East Biopharmaceutical CMO Market Size and Forecast by Source, 2021-2031, ($Million)
8.5.7.3. Middle East Biopharmaceutical CMO Market Size and Forecast by Service, 2021-2031, ($Million)
8.5.8. Africa
8.5.8.1. Africa Biopharmaceutical CMO Market Size and Forecast By Product, 2021-2031, ($Million)
8.5.8.2. Africa Biopharmaceutical CMO Market Size and Forecast by Source, 2021-2031, ($Million)
8.5.8.3. Africa Biopharmaceutical CMO Market Size and Forecast by Service, 2021-2031, ($Million)

Chapter 9. Competitive Landscape
9.1. Market Overview
9.2. Market Share Analysis/Key Player Positioning
9.3. Developmental Strategy Benchmarking
9.3.1. New Product Development
9.3.2. Product Launches
9.3.3. Business Expansions
9.3.4. Partnerships, Joint Ventures, and Collaborations
9.3.5. Mergers and Acquisitions

Chapter 10. Company Profiles
10.1. Toyobo Co. Ltd.
10.1.1. Company Snapshot
10.1.2. Financial Performance
10.1.3. Product Offerings
10.1.4. Key Strategic Initiatives
10.1.5. SWOT Analysis
10.2. Samsung Biologics
10.2.1. Company Snapshot
10.2.2. Financial Performance
10.2.3. Product offerings
10.2.4. Key Strategic Initiatives
10.2.5. SWOT Analysis
10.3. Patheon
10.3.1. Company Snapshot
10.3.2. Financial Performance
10.3.3. Product offerings
10.3.4. Key Strategic Initiatives
10.3.5. SWOT Analysis
10.4. Lonza AG
10.4.1. Company Snapshot
10.4.2. Financial Performance
10.4.3. Product offerings
10.4.4. Key Strategic Initiatives
10.4.5. SWOT Analysis
10.5. WuXi Biologics
10.5.1. Company Snapshot
10.5.2. Financial Performance
10.5.3. Product offerings
10.5.4. Key Strategic Initiatives
10.5.5. SWOT Analysis
10.6. AbbVie Inc.
10.6.1. Company Snapshot
10.6.2. Financial Performance
10.6.3. Product offerings
10.6.4. Key Strategic Initiatives
10.6.5. SWOT Analysis
10.7. Biner Co. Ltd.
10.7.1. Company Snapshot
10.7.2. Financial Performance
10.7.3. Product offerings
10.7.4. Key Strategic Initiatives
10.7.5. SWOT Analysis
10.8. JRS Pharma
10.8.1. Company Snapshot
10.8.2. Financial Performance
10.8.3. Product offerings
10.8.4. Key Strategic Initiatives
10.8.5. SWOT Analysis
10.9. Biomeva GmbH
10.9.1. Company Snapshot
10.9.2. Financial Performance
10.9.3. Product offerings
10.9.4. Key Strategic Initiatives
10.9.5. SWOT Analysis
10.10. ProBrioGen AG
10.10.1. Company Snapshot
10.10.2. Financial Performance
10.10.3. Product offerings
10.10.4. Key Strategic Initiatives
10.10.5. SWOT Analysis

*The list of company is subject to change during the final compilation of the report
Market Segments

By Product

  • Biologics
  • Biosimilars

By Source

  • Mammalian
  • Non-mammalian

By Service

  • Contract Manufacturing
  • Process Development
  • Packaging
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • The UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • The Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World
    • Latin America
    • The Middle East
    • Africa

Order this Report

Have questions about the scope of the report ?

Have specific requirements ?

Budget Constraints ?

Related Reports

Bioremediation technology is the use of living organisms…
The global Compartment Syndrome Monitoring Devices Market was…
Sulfasalazine, also known by its brand name Azulfidine,…
Alopecia is a condition that results in hair…
Diabetic retinopathy is a censorious medical disorder that…
Methicillin-Resistant Staphylococcus Aureus (MRSA) is a type of…
Eleuthero (Eleutherococcus senticosus) is an herb that has…
The global Disposable Pipette Tips Market was valued…
Monoclonal antibody therapy is a treatment that uses…
Cystic Fibrosis (CF) is a progressive, genetic disease…